Showing results (1-10 of 316) with videos related to

Sort By:
Pageof 32
Diseases (Basel, Switzerland)|April 25, 2025
Beneficial Probiotics with New Cancer Therapies for Improved Treatment of Hepatocellular CarcinomaMoeka Nakashima, Akari Fukumoto, Satoru Matsuda
Non-Coding RNA|November 24, 2025
Prolonged Survival with Dieting for Improved AutophagyAkari Fukumoto, Moeka Nakashima, Satoru Matsuda
Nutrients|April 12, 2025
N6-Methyladenosine Modification in the Metabolic Dysfunction-Associated Steatotic Liver DiseaseSatoru Matsuda, Moeka Nakashima, Akari Fukumoto, et al.
Discovery Medicine|April 27, 2025
GPCRs With mTOR Signaling Expressed in Gut-Brain-Immune Axis-Cells Could Contribute to the Treatment of Neurodegenerative Diseases and Immune-Related DiseasesAkari Fukumoto, Naoko Suga, Moeka Nakashima, et al.
International Journal of Physiology, Pathophysiology and Pharmacology|January 24, 2025
Comprehension of gut microbiota and microRNAs may contribute to the development of innovative treatment tactics against metabolic disorders and psychiatric disordersMoeka Nakashima, Naoko Suga, Akari Fukumoto, et al.
International Journal of Physiology, Pathophysiology and Pharmacology|November 25, 2024
Caveolae with serotonin and NMDA receptors as promising targets for the treatment of Alzheimer's diseaseMoeka Nakashima, Naoko Suga, Akari Fukumoto, et al.
Oncology Research|April 29, 2025
Promising roles of vitamin D receptor and APRO family proteins for the development of cancer stem cells targeted malignant tumor therapyMoeka Nakashima, Naoko Suga, Akari Fukumoto, et al.
Discovery Medicine|November 27, 2024
Exosomes, Endosomes, and Caveolae as Encouraging Targets with Favorable Gut Microbiota for the Innovative Treatment of Alzheimer's DiseasesMoeka Nakashima, Naoko Suga, Akari Fukumoto, et al.
Oncology Research|September 8, 2025
Association among Noncoding-RNAs, APRO Family Proteins, and Gut Microbiota in the Development of Breast CancerAkari Fukumoto, Satoru Matsuda
Molecules (Basel, Switzerland)|August 29, 2024
Caveolae with GLP-1 and NMDA Receptors as Crossfire Points for the Innovative Treatment of Cognitive Dysfunction Associated with Neurodegenerative DiseasesMoeka Nakashima, Naoko Suga, Sayuri Yoshikawa, et al.
Pageof 32